Dishman Carbogen Amcis Ltd

Dishman Carbogen Amcis has shown notable trading activity, rebounding from an early loss to reach an intraday high. The stock's performance has outpaced its sector, despite recent volatility and a decline over the past month, indicating a complex market position for the company.

Dishman Carbogen Amcis has faced notable volatility, with its stock declining significantly today, underperforming against its sector. The stock reached an intraday low and has seen a concerning decrease over the past month. Its performance relative to moving averages indicates mixed results amid competitive market challenges.

Dishman Carbogen Amcis has announced its financial results for the quarter ending December 2024, showing significant year-on-year growth in both Profit Before Tax and Profit After Tax. However, the company faces challenges, including increased interest expenses and a declining Debtors Turnover Ratio, indicating mixed performance in the pharmaceuticals sector.

Dishman Carbogen Amcis has experienced notable trading activity, gaining 7.18% on February 4, 2025, significantly outperforming its sector. The stock's performance reflects mixed trends in moving averages, with a recent decline over the past month contrasting with its strong one-day performance compared to the Sensex.

Dishman Carbogen Amcis has experienced notable trading activity, gaining 7.18% on February 4, 2025, significantly outperforming its sector. The stock's performance reflects mixed trends in moving averages, with a recent decline over the past month contrasting with its strong one-day performance compared to the Sensex.

Dishman Carbogen Amcis has faced notable volatility, experiencing a decline of 7.05% on January 27, 2025. The stock has underperformed its sector and declined 18.04% over the past month, contrasting with the Sensex's smaller dip. Its position relative to moving averages indicates mixed performance and potential challenges ahead.

Dishman Carbogen Amcis has experienced a revision in its score following a strong performance, gaining over 7% on January 1, 2025. The stock's upward trajectory over recent days and its position above key moving averages reflect robust short-term performance, leading to its addition to MarketsMOJO's list.

Dishman Carbogen Amcis has experienced a revision in its stock evaluation following a recent decline in price. Despite this adjustment, the company continues to trade above its key moving averages, indicating resilience. Additionally, it has been added to MarketsMOJO's list, highlighting its potential in the pharmaceutical sector. Investors are advised to monitor its performance closely.

Dishman Carbogen Amcis has recently experienced a notable adjustment in its evaluation, reflecting its strong market performance and significant price increase over the past year. The stock has been added to MarketsMOJO's list, highlighting its potential in the pharmaceutical sector despite a cautious 'Sell' call from analysts.

Dishman Carbogen Amcis has recently been added to MarketsMOJO's list following a revision in its score, reflecting its impressive performance in the pharmaceutical sector. The stock has achieved a 52-week high and demonstrated significant gains over the past year, outperforming the broader market, indicating strong investor interest and market confidence.

Dishman Carbogen Amcis has recently experienced a revision in its score, reflecting its strong market performance and significant year-over-year growth. The stock, which recently reached a 52-week high, has been added to MarketsMOJO's list, highlighting its potential in the pharmaceutical sector despite a recent minor dip.

On November 22, 2024, Dishman Carbogen Amcis, a smallcap pharmaceutical company, saw a significant increase in its stock price, gaining 8.34% and closing at Rs 234.85. The stock has been on a consecutive gain for the last two days, outperforming the sector by 7.73%. It is currently trading higher than its moving averages and has outperformed the Sensex in the last month.

On November 18, 2024, Dishman Carbogen Amcis, a smallcap pharmaceutical company, saw a 7.6% increase in its stock price, outperforming the sector by 7.83%. The stock has been on a consecutive gain for the past two days, reaching an intraday high of Rs 228.75. It is currently trading above its moving averages, indicating a positive trend.

Dishman Carbogen Amcis, a smallcap pharmaceutical company, has reported a strong financial performance in the second quarter of fiscal year 2024-25. The company's PBT and PAT have shown significant growth, while its operating profit and cash flow have also improved. However, the increasing debt and interest cost may pose a potential risk.

On November 14th, 2024, Dishman Carbogen Amcis, a smallcap pharmaceutical company, experienced a surge in stock price of 9.77%, outperforming the sector by 10.28%. The stock has consistently performed well, trading higher than its moving averages and outperforming the overall market, with a 12.78% increase in the past month compared to the Sensex's -5.09% decrease.

On November 13, 2024, Dishman Carbogen Amcis, a smallcap pharmaceutical company, experienced a -7.0% decline in its stock price, in line with the underperformance of the pharmaceuticals and drugs industry. According to MarketsMOJO, the company has been given a 'Strong Sell' rating based on recent performance and market trends. The stock is currently trading below its moving averages and has underperformed the market and Sensex, indicating potential challenges for the company.

On October 17th, 2024, Dishman Carbogen Amcis, a smallcap pharmaceutical company, saw a 7.59% increase in its stock price, outperforming the sector by 8.42%. This marks the third consecutive day of gains, with a total increase of 12.15%. The stock is currently trading higher than its moving averages, indicating a positive trend. However, MarketsMOJO has given a 'Strong Sell' call, suggesting caution for investors.

On August 21, 2024, Dishman Carbogen Amcis, a smallcap pharmaceutical company, saw a 7.19% increase in its stock price, outperforming the sector by 6.46%. The stock had previously fallen for two days, but has now gained momentum with an intraday high of Rs 184.7. MarketsMOJO has given a 'Strong Sell' call, but this is a fact-based analysis and does not include any external opinions or recommendations.